x
ServiziMenu principaleHome
You are here:  > Educational Opportunities > Past events > 2013 > Leukaemia and Lymphoma
Share on Share on Facebook Twitter Share on Linkedin Share on WhatsApp Share on Instagram Share by email Print this page

Leukaemia and Lymphoma

12 ESCO credits

15.06.2013  -  17.06.2013

Ascona, Switzerland

COURSES AND SEMINARS

Haemato-oncology, Leukaemia, Lymphoma

*Third party registration should be used if you are requesting an individual registration for someone who is not you.
Please note that website registration under your name will be needed before registering someone else to this event.

Description

Chairs: M.F. Fey, CH - J.O.Armitage, US - E. Zucca, CH
Hosting Chair: F.Cavalli, CH


Dear Colleagues,

Over the past twenty years or so, this course has become a renowned programme for physicians and scientists with an interest in the diagnosis and treatment of haematological cancers. It typically draws participants from most if not all continents and thus allows for a stimulating truly international gathering of colleagues interested in lymphoma and leukaemia. Oncology or haematology trainees are just as welcome as are experienced colleagues looking for a refresher course.

The international faculty, including ICML key note lecturers, will guide us through the complexity of the biology and the most relevant clinical problems in leukaemia and lymphoma, offering plenary lectures, practice-oriented training through case presentations, workshops in small groups and ample discussion slots. Care will be taken to avoid duplications of presentations later scheduled for the Lugano Conference.
The format of the residential course will furthermore offer opportunities for informal exchange of ideas, views and experience among the participants and with the faculty.

The close co-operation between the ESO Course Chairmen and the ICML Committee will assure an optimal co-ordination of the topics between the course and the ICML Congress.  A particular feature of the Ascona course will be to include topics and presentations that are important in the field but benefit from the smaller format emphasising clinical judgment and individualisation of treatment, thus complementing the presentations typically offered at large and busy conferences.

Attendance to the course will be by registration on a first-come/first-served basis. However, to respect the layout and objectives of the course, attendance will be limited to 80 participants.

We are much looking forward to meeting and working with you at the beautiful campus on Monte Verità near Ascona, in the lovely Italian-speaking South of Switzerland.

Yours sincerely,

Martin F. Fey - James O. Armitage - Emanuele Zucca
Course Chairs



PARTICIPANT'S PROFILE 
The programme is designed for postgraduate medical doctors at any stage of clinical career who are interested in haematological oncology. A mix of experienced clinicians or pathologists etc., and oncology/haematology trainees is welcome.
Scientists (PhD) are very welcome too, but they should be advised that the course will emphasise clinical aspects rather than basic biology.


LEARNING OBJECTIVES
• Learn or reinforce knowledge on modern diagnostic tools in haemato-oncology
• Understand the molecular pathology of leukaemia and lymphoma
• Retain the salient clinical features of important lymphoma or leukaemia entities
• Discuss and weigh evidence favouring particular treatment options in haematological oncology
• Learn how to handle complications of treatment for lymphoma and leukaemia

General information

ORGANISING SECRETARIAT AND REGISTRATION
European School of Oncology, ESO Bellinzona Office
Piazza Indipendenza 2, 6500 Bellinzona, Switzerland
Ph +41 91 820 0952, fx +41 91 820 0953
dknupfer@eso.net 


VENUE
The course will be held at the Centro Congressi Monte Verità (www.monteverita.org) in Ascona (Southern Switzerland) located on a beautiful hill overlooking Ascona and the Lago Maggiore.
The airport of reference is Lugano. The Malpensa Airport will not be served with transfers.


ARRIVAL AND DEPARTURE TRANSFERS
Transfers will be organised at given times for arrivals on Saturday, 15 June and for departures on Tuesday, 18 June as indicated in the tables below.
After having registered to the course, participants will be offered the option to register to the transfers as well.


Arrivals - Saturday, 15 June

Location 

Pick up time 

Arrival at venue 

Lugano airport 

 13:50 

 14:50 

Lugano railway station

13:00

 14:00 

Locarno railway station

13:15

13:45


Departures - Tuesday, 18 June

From course venue to:

Departure time 

Arrival time 

Lugano airport

 8:30

  9:30 

Lugano railway station

 8:30

 9:30

Locarno railway station

 8:30

 9:00



CME ACCREDITATION
All participants will be able to print their own certificate on the completion of the online evaluation form.

The Leukaemia and Lymphoma course is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.
The Leukaemia and Lymphoma course  is designated for up to 15 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

The programme is furthermore accredited with 21 ESMO-MORA category 1 points.


HANS WYDER FELLOWSHIPS
A limited number of Hans Wyder fellowships are available to cover registration, accommodation (in sharing room) and travel costs.
Fellowships are restricted to participants below the age of 40 coming from countries defined as low-income economies by the World Bank http://data.worldbank.org/about/country-classifications/country-and-lending-groups
To apply for a fellowship, please provide ESO by 1st March 2013 with your short CV (including date of birth), letter describing the motivation to attend the course and an indication of the amount required to cover travel costs.


INSURANCE
The organisers bear no responsibility for untoward events in connection with, before, during and after the course. Participants are advised to take out their own personal and travel insurance coverage.


12th INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA
The ESO course is held in co-operation with the Organising Committee and will precede the 12th ICML (19-22 June 2013, Lugano, Switzerland). The 12-ICML conference will provide the worldwide most important forum for the discussion of all aspects relating to malignant lymphoma.
ICML and the ESO course are two separate events that require registration to one or the other, or both.
For further information please contact cristiana.brentan@lymphcon.ch or visit www.lymphcon.ch

Faculty list


FACULTY
J.O. Armitage
, University of Nebraska Medical Centre, Hematology-Oncology Section, Nebraska, US
P.L. Bergsagel, Department of Therapeutics for Cancer Research, Mayo Clinic in Arizona, Arizona, US 
F. Cavalli, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, CH
T. Cerny, Cantonal Hospital St. Gallen, Department of Internal Medicine, St. Gallen, CH
M.F. Fey, Berne University, Inselspital, Department of Medical Oncology and Haematology, Berne, CH
J. Heverhagen, Berne University, Inselspital, Department of Radiology, Neuro-radiology and Nuclear medicine, Berne, CH
T.A. Lister, St. Bartholomew's Hospital, Department of Medical Oncology, London, UK
L. Mazzucchelli, Cantonal Institute of Pathology in Southern Switzerland, Locarno, CH
G. Merlini, University of Pavia, Department of Molecular Medicine, Pavia, IT
A. Neubauer, Philipps University, Department of Hematology/Oncology, Marburg, DE
U. Novak, Berne University, Inselspital, Department of Medical Oncology and Haematology, Berne, CH
T. Pabst, Berne University, Inselspital, Department of Medical Oncology and Haematology, Berne, CH
A. Rauch, Berne University, University, Inselspital, Department of Infectiology, Berne, CH
R. Schlenk, University of Ulm, Department  of Internal Medicine 3, Haematology and Oncology, Ulm, DE
S. Stilgenbauer, University of Ulm, Department  of Internal Medicine 3, Haematology and Oncology, Ulm, DE
S. Treon, Dana Farber Cancer Institute, Harvard Medical School, Bing Centre for Waldenstrom's Macroglobulinemia, Boston, US
J.M. Vose, University of Nebraska Medical Centre, Hematology-Oncology Section, Nebraska, US
R. Willemze,  Leiden University Medical Center, Department of Dermatology, Leiden, NL
E. Zucca, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, CH

Programme

15 JUNE

14:00

Registration

 15:00 

Introduction to the course 
M.F. Fey, CH and J.O. Armitage, US 

 15:15

Symposium Basics in haemato-oncology 
Chair: F. Cavalli, CH

 

15:15 The hematological  stem cell 
         A.Neubauer, CH
15:45
Molecular genetics of myeloid neoplasia 
         A. Neubauer, CH
16:15
Molecular genetics of lymphoma  
         U. Novak, CH
16:45
Principles of clinical trial design in haematological oncology
         M.F. Fey, CH

17:30

Coffee break

 18:00 

Workshop sessions I (4 groups, rotating) 
J. Heverhagen, CH
 Group 1 Imaging problems in haemato-oncology
            (case discussions)                M.F. Fey , CH and J. Heverhagen, CH 
Group 2 
Strategies in cancer patients with neutropenia and fever                (case discussions)              A. Rauch , CH
Group 3 
Lymphoma pathology seminar  
            L. Mazzucchelli, CH
Group 4 
Molecular diagnostics of leukaemias  
            T. Pabst, CH
 19:30 Dinner 

 

16 JUNE

 8:30

Workshop sessions II (4 groups, rotating) 
 Group 2 Imaging problems in haemato-oncology (case                discussions)             M.F. Fey, CH and J. Heverhagen, CH
Group 3 
Strategies in cancer patients with neutropenia and fever               (case discussions)  
            A. Rauch, CH
Group 4 
Lymphoma pathology seminar  
            L. Mazzucchelli, CH
Group 1 
Molecular diagnostics of leukaemias  
            T. Pabst, CH

10:00

Coffee break

10:30

Symposium: Lymphoma I 
Chair: T.A. Lister, UK

 

10:30 Controversial issues in the management of follicular             lymphoma 
         J.O. Armitage, US
11:00
Problems of mantle cell lymphoma 
         E. Zucca, CH
11:30
Developing management standards for patients with             peripheral T-cell lymphoma  
         J.M. Vose, US
12:00 Allogeneic SCT in lymphoma: To do or not to do?         T.A. Lister, UK

12:30

Lunch 

14:00

Chronic myeloproliferative disorders other than CML
A. Neubauer, DE
 

14:45

Symposium: Lymphoma II 
Chair: J.O. Armitage, US
 14:45 The standard therapy for Hodgkin's disease  
         T.A. Lister, UK
15:15 Cutaneous lymphomas: Tricky treatment decisions
         R. Willemze, CH
15:45
Salient features of rare lymphoma subtypes 
         J.O. Armitage, US

16:30

Coffee break 

17:00

Workshop sessions III (4 groups, rotating) 
 Group 3 Imaging problems in haemato-oncology (case                discussions)  
            M.F. Fey, CH and J. Heverhagen, CH
Group 4 
Strategies in cancer patients with neutropenia and                fever (case discussions)  
            A. Rauch, CH
Group 1 
Lymphoma pathology seminar  
            L. Mazzucchelli, CH
Group 2 
Molecular diagnostics of leukaemias  
            T. Pabst, CH

 19:15   

Dinner 
  

17 JUNE

 9:00

Workshop sessions IV  (4 groups, rotating) 
 Group 4 Imaging problems in haemato-oncology (case                discussions)                        M.F. Fey, CH and J. Heverhagen, CH
Group 1 
Strategies in cancer patients with neutropenia and fever
           
(case discussions)  
            A. Rauch, CH
Group 2 
Lymphoma pathology seminar  
            L. Mazzucchelli, CH
Group 3 
Molecular diagnostics of leukaemias  
            T. Pabst, CH

10:30

Coffee break

 11:30 

Symposium: Myeloma  
Chair: T. Cerny, CH
 11:00 Current treatment standards for myeloma  
         P.L. Bergsagel, NL
11:45
Management of Waldenström's disease  
         S. Treon, US
 12:30Lunch 
 14:00Symposium: Troublesome immunoglobulins 
Chair: E. Zucca, CH
 14:00 Amyloidosis  
         G. Merlini, IT
14:30
MGUS  
         S. Treon, US

 15:00

Coffee break 

15:30

Symposion: Leukaemias  
Chair: R. Schlenk, DE
 

15:30 Acute myeloblastic leukaemias: Advances in therapy (if            any) 
         R. Schlenk, DE
16:15 Chronic lymphocytic leukaemia  
         S. Stilgenbauer, DE
17:00 Lymphoma in the elderly  
         T. Cerny, CH

 

18 JUNE

TBC

Departures